Pretreatment Nomogram Predicting Ten-Year Biochemical Outcome of Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Prostate Cancer - 09/08/11
, Michael W. Kattan c, Paul Fearn b, Bertha L. Fearon a, Jason P. Stasi b, Alison M. Shippy a, Peter T. Scardino b
Reprint requests: Michael J. Zelefsky, M.D., Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.Résumé |
Objectives |
To update our previously published nomogram predicting for biochemical outcome with 10-year data from a larger cohort of patients treated with three-dimensional conformal radiotherapy (RT) or intensity-modulated RT for localized prostate cancer.
Methods |
From 1988 to 2004, 2253 patients were treated with three-dimensional conformal RT or intensity-modulated RT for clinical Stage T1-T3 prostate cancer. Prescription doses ranged from 64.8 to 86.4 Gy. The median follow-up time was 7 years. The nomogram was developed using a proportional hazards regression model predicting for the probability of biochemical relapse after RT according to the nadir plus 2 ng/mL definition of prostate-specific antigen (PSA) relapse.
Results |
The 10-year PSA relapse-free survival rate was 62%. The nomogram incorporated the following variables to predict likelihood of PSA failure after RT: pretreatment PSA level, Gleason score, radiation dose, use of neoadjuvant androgen deprivation, and clinical stage. The concordance index of this long-term nomogram was 0.72.
Conclusions |
A nomogram predicting the 10-year probability of biochemical control after three-dimensional conformal RT or intensity-modulated RT for prostate cancer was reasonably accurate and discriminating. The nomogram also provided evidence that long-term biochemical control can be achieved after conformal RT for the treatment of localized prostate cancer.
Le texte complet de cet article est disponible en PDF.Plan
Vol 70 - N° 2
P. 283-287 - août 2007 Retour au numéro
Article précédent
- Risk Stratification of Men with Gleason Score 7 to 10 Tumors by Primary and Secondary Gleason Score: Results from the SEARCH Database
- David E. Kang, Nicholas J. Fitzsimons, Joseph C. Presti, Christopher J. Kane, Martha K. Terris, William J. Aronson, Christopher L. Amling, Stephen J. Freedland, SEARCH Database Study Group
- Effect of Definition of Preradiotherapy Prostate-Specific Antigen Velocity on Its Association with Prostate Cancer-Specific Mortality and All-Cause Mortality
- Paul L. Nguyen, Ming-Hui Chen, Andrew A. Renshaw, Brenda Sussman, Anthony V. D’Amico
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?